New hope for advanced cancer patients as experimental drug JSKN021 enters first human tests
NCT ID NCT07617727
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug, JSKN021, in about 199 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also look for signs that the drug shrinks tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hospital of Jining Medical College
RECRUITINGJining, Shandong, China
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, China
-
Tumor Hospital of Guangxi Medical University
RECRUITINGNanning, Guangxi, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, China
-
Xuzhou Central Hospital
RECRUITINGXuzhou, Jiangsu, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo targets Hard-to-Treat cancers
- New drug combo takes on advanced cancers
- Experimental injection trains immune cells inside the body to fight cancer
- New combo therapy takes on advanced cancers
- New drug CS231295 enters first human trial for tough cancers
- New hope for advanced cancer: AK150 drug trial launches